Search results for " BIOMARKERS"

showing 10 items of 365 documents

Cardiac involvement in patients with cirrhosis: a focus on clinical features and diagnosis

2016

Cirrhotic heart has been traditionally considered protected from cardiovascular disease, even if a large amount of literature has recently shown that patients affected by chronic liver disease are exposed to cardiovascular events, as well. Since the first recognition of cardiac involvement in cirrhosis, all published studies explain that decompensated cirrhotic patients suffer from haemodynamic changes, currently known as hyperdynamic syndrome, which finally lead to cirrhotic cardiomyopathy. This is defined by the presence of a subclinical systolic dysfunction unmasked under stress conditions, impaired diastolic function and electrophysiological abnormalities, in the absence of any known ca…

Liver Cirrhosismedicine.medical_specialtyCirrhosisSettore MED/09 - Medicina InternaHemodynamicsDisease030204 cardiovascular system & hematologyChronic liver diseaseGastroenterology03 medical and health sciencesElectrocardiography0302 clinical medicineSerum biomarkersInternal medicinemedicineHumansIn patientSubclinical infectioncardiac function cardiomyopathy cirrhosisbusiness.industryGeneral Medicinemedicine.diseasePrognosisMagnetic Resonance ImagingCirrhotic cardiomyopathyEchocardiography Doppler030211 gastroenterology & hepatologyCardiology and Cardiovascular MedicinebusinessCardiomyopathiesBiomarkers
researchProduct

Into the wild of long non-coding RNA in gastrointestinal stromal tumors (GISTs) to explore new prognostic/predictive biomarkers

2015

Background: Long Non-coding RNAs (lncRNA) are emerging as essential regulators of genetic and epigenetic networks, and their deregulation may underlie complex diseases, such as carcinogenesis. Several studies have described lncRNAs alterations in patients with solid tumors. In particular, in Gastrointestinal Stromal Tumors (GIST), upregulation of HOTAIR has been associated with aggressiveness, metastasis, and poor patients’ survival. In order to gain more detailed insight on the molecular role of lncRNAs in GIST, we analyzed in vivo the expression levels of lncRNAs H19 and MALAT1 in surgically resected patients. Material and Methods: The expression of the lnc-RNAs H19 and MALAT1 was evaluat…

Long non coding RNAs Gastrointestinal Stromal Tumors prognostic/predictive biomarkers
researchProduct

Immunomodulation and physiological responses of Mytilus galloprovincialis as bioindicators of environmental change

2015

Immunomodulation and physiological responses of Mytilus galloprovincialis as bioindicators of environmental change Oxygenation level temperature increases and changes in food availability are predicted to occur in the future. In such scenario, a global climate change (GCC), there is growing concern for the health status of wild and farmed organisms. Bivalve molluscs, are important components of coastal marine ecosystems, and as sedentary and filter feeders, are good bioindicators of environmental conditions. The ability of organisms to maintain the immunosurveillance unaltered under adverse environmental conditions may enhance theirs survival capability. Only a few studies have investigated…

M. galloprovincialis biomarkers environmental stressors
researchProduct

LncRNA H19, HOTAIR and MALAT1 as prognostic molecular biomarkers in GIST

2017

MALAT1OncologyGiSTbusiness.industryCancer researchMedicineHOTAIRHematologybusinessMolecular biomarkersAnnals of Oncology
researchProduct

On the Road to Accurate Biomarkers for Cardiometabolic Diseases by Integrating Precision and Gender Medicine Approaches

2019

The need to facilitate the complex management of cardiometabolic diseases (CMD) has led to the detection of many biomarkers, however, there are no clear explanations of their role in the prevention, diagnosis or prognosis of these diseases. Molecules associated with disease pathways represent valid disease surrogates and well-fitted CMD biomarkers. To address this challenge, data from multi-omics types (genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics, and nutrigenomics), from human and animal models, have become available. However, individual omics types only provide data on a small part of molecules involved in the complex CMD mechanisms, whereas, here, we pr…

Male0301 basic medicineGenomicsReviewaccurate CMD biomarkersDiseaseComputational biology030204 cardiovascular system & hematologyProteomicsCatalysisInorganic Chemistry03 medical and health sciences0302 clinical medicineMetabolic DiseasesGender medicineAnimalsHumansMedicinePrecision MedicinePhysical and Theoretical ChemistryMolecular BiologySpectroscopyEpigenomicscardiometabolic diseasebusiness.industrygender medicineOrganic ChemistryMultidimensional dataComputational BiologyGeneral MedicineOmicsComputer Science Applicationsaccurate CMD biomarker030104 developmental biologyNutrigenomicsCardiovascular DiseasesFemalemulti-omics integrationcardiometabolic diseasesbusinessBiomarkersmanagementInternational Journal of Molecular Sciences
researchProduct

Analysis of RET promoter CpG island methylation using methylation-specific PCR (MSP), pyrosequencing, and methylation-sensitive high-resolution melti…

2016

Background Already since the 1990s, promoter CpG island methylation markers have been considered promising diagnostic, prognostic, and predictive cancer biomarkers. However, so far, only a limited number of DNA methylation markers have been introduced into clinical practice. One reason why the vast majority of methylation markers do not translate into clinical applications is lack of independent validation of methylation markers, often caused by differences in methylation analysis techniques. We recently described RET promoter CpG island methylation as a potential prognostic marker in stage II colorectal cancer (CRC) patients of two independent series. Methods In the current study, we analy…

Male0301 basic medicineMESH: Sequence Analysis DNABisulfite sequencingAnalytic sensitivityMS-HRMMESH : AgedMESH : Promoter Regions GeneticPolymerase Chain Reaction[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineMESH: DNA MethylationMESH : FemaleMESH : Proto-Oncogene Proteins c-retPromoter Regions GeneticMESH: CpG IslandsMESH : Polymerase Chain ReactionGenetics (clinical)MESH: AgedDNA methylationMESH : PrognosisMethylationMESH : CpG IslandsPrognosispyrosequencing030220 oncology & carcinogenesisMESH: Survival AnalysisDNA methylationFemaleMESH : Colorectal NeoplasmsMESH : Sensitivity and SpecificityColorectal NeoplasmsMESH : Male[SDV.CAN]Life Sciences [q-bio]/CancerBiologySensitivity and SpecificityMESH: Proto-Oncogene Proteins c-retHigh Resolution MeltMESH: Prognosis03 medical and health sciencesMESH: Promoter Regions GeneticGeneticsHumansMolecular BiologyAgedMESH: HumansResearchMSPProto-Oncogene Proteins c-retMESH : HumansMESH: Polymerase Chain ReactionSequence Analysis DNASurvival AnalysisMolecular biologyMESH: Sensitivity and SpecificityMESH: Male030104 developmental biologyPyrosequencingIllumina Methylation AssayCpG IslandsCancer biomarkersClinical sensitivityPrimer (molecular biology)MESH : Survival AnalysisRETMESH: FemaleMESH : DNA MethylationMESH: Colorectal NeoplasmsDevelopmental BiologyMESH : Sequence Analysis DNA
researchProduct

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort…

2021

BackgroundCheckpoint inhibitors revolutionized the treatment of metastatic melanoma patients. Although tumor burden and lactate dehydrogenase (LDH) are associated with overall survival (OS), the impact of tumor growth kinetics remains elusive and in part contradictory. The aims of this study were to develop a novel simple and rapid method that estimates pretreatment metastatic growth rate (MGR) and to investigate its prognostic impact in melanoma patients treated with antiprogrammed death receptor-1 (PD-1) antibodies.MethodsMGR was assessed in three independent cohorts of a total of 337 unselected consecutive metastasized stage IIIB–IV melanoma patients (discovery cohort: n=53, confirmation…

Male0301 basic medicineOncologyCancer ResearchSkin NeoplasmsTime Factors2437Programmed Cell Death 1 ReceptorPembrolizumabMetastasis0302 clinical medicineRisk FactorsImmunotherapy BiomarkersImmunology and Allergy1506Immune Checkpoint InhibitorsRC254-282MelanomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensMiddle Agedddc:EuropeNivolumabTreatment OutcomeOncology030220 oncology & carcinogenesisCohortMolecular MedicineFemaleimmunotherapyNivolumabCohort studytumormedicine.medical_specialtyImmunologyAntibodies Monoclonal HumanizedRisk Assessment03 medical and health sciencesPredictive Value of TestsInternal medicinemelanomamedicineHumansCell ProliferationNeoplasm StagingRetrospective StudiesPharmacologyProportional hazards modelbusiness.industrybiomarkersReproducibility of Resultsmedicine.disease030104 developmental biologyTomography X-Ray ComputedbusinessBrain metastasis
researchProduct

Genetic systems for a new approach to risk of progression of diabetic retinopathy.

2016

OBJECTIVE: To evaluate the risk of progression of diabetic retinopathy (DR) using new strategies to obtain genetic information in type 2 diabetes (T2D) based on interfering ribonucleic acid (RNA). MATERIAL AND METHODS: A prospective multicentre case-control study of 132 participants was distributed into: T2D with (+DR) or without (-DR) (T2DG; n=77), and a control group (CG; n=55). After an eye examination and personal interview, tears were collected for molecular analysis (expression of microRNAs [miRNAs] (miRCURY ARN Isolation Kit, Qiagen)]. Libraries, 137 vs. 140bp (GeneMapper, Applied Biosystems), were obtained in 18 samples (T2DG+DR=6; T2DG-DR=6; CG=6) by performing next-generation sequ…

Male0301 basic medicineOncologyMicro RNAsmedicine.medical_specialtyBiomarcadores preclinicosType 2 diabetesMicro-ARNBioinformaticsRisk AssessmentInterference by RNA03 medical and health sciencesDiabetic retinopathyInternal medicineType 2 diabetes mellitusmedicineHumansProspective StudiesFamily historyAgedDiabetic Retinopathymedicine.diagnostic_testSequence Analysis RNAbusiness.industryPre-clinical biomarkersType 2 Diabetes MellitusGenetic systemsRetinopatia diabeticaGeneral MedicineDiabetic retinopathyMiddle Agedmedicine.diseaseInterferencia por ARNMolecular analysisDiabetes mellitus tipo 2030104 developmental biologyDiabetes Mellitus Type 2Eye examinationCase-Control StudiesDisease ProgressionTearsFemalebusinessBiomarcadores preclínicos Diabetes mellitus tipo 2 Diabetic retinopathy Interference by RNA Interferencia por ARN Micro RNAs Micro-ARN Pre-clinical biomarkers Retinopatía diabética Type 2 diabetes mellitus
researchProduct

Anti-Inflammatory Effects of the Mediterranean Diet in the Early and Late Stages of Atheroma Plaque Development

2017

Objective.To evaluate the long-term effects of a Mediterranean diet (MeDiet) intervention on the plasma concentrations of inflammatory and plaque stability-related molecules in elderly people at high risk for cardiovascular disease.Design and Setting. 66 participants from primary care centers affiliated with the Hospital Clinic of Barcelona were randomized into 3 groups: MeDiet plus extra virgin olive oil (EVOO) or nuts and a low-fat diet (LFD). At baseline and at 3 and 5 years, we evaluated the changes in the plasma concentrations of 24 inflammatory biomarkers related to the different stages of the atherosclerotic process by Luminex®.Results.At 3 and 5 years, both MeDiet groups showed a si…

Male0301 basic medicinePathologyMediterranean dietHigh-risk030204 cardiovascular system & hematologyDiet MediterraneanDieta mediterràniaGastroenterology0302 clinical medicineRisk FactorsElderly peopleChemokine CCL4Chemokine CCL5Diet Fat-RestrictedAged 80 and overBioquímica y tecnologíaInterleukin-18Middle AgedInflammatory biomarkersPlaque AtheroscleroticInterleukin-10Lipoproteins LDLBiochemistry and technologyCardiovascular diseasesCardiovascular DiseasesPlasma concentrationCytokinesFemalelcsh:RB1-214medicine.medical_specialtyArticle Subjectmedicine.drug_classImmunologyVascular Cell Adhesion Molecule-1ActivationPrimary careBioquímica i biotecnologiaLow-grade inflammationAnti-inflammatory03 medical and health sciencesMediterranean cookingElderly personsCardiovascular-diseaseInternal medicineCuina mediterrànialcsh:PathologymedicineHumansAgedMarkers030109 nutrition & dieteticsInterleukin-6Malalties cardiovascularsbusiness.industryPatternCell Biologymedicine.diseaseAtherosclerosisAtheromaClinical Study0962-9351Placa ateroscleròticabusiness
researchProduct

Urinary exosome miR-146a is a potential marker of albuminuria in essential hypertension

2018

Abstract Background There is increasing interest in using extracellular vesicle-derived microRNAs (miRNAs) as biomarkers in renal dysfunction and injury. Preliminary evidence indicates that miRNAs regulate the progression of glomerular disease. Indeed, exosomes from the renal system have provided novel evidence in the clinical setting of albuminuria. Thus, the aim of this study was to quantify the urinary miRNAs present in exosome and microvesicles (MVs), and to assess their association with the presence of increased urinary albumin excretion in essential hypertension. Methods Exosomes were collected from urine specimens from a cohort of hypertensive patients with (n = 24) or without albumi…

Male0301 basic medicinemedicine.medical_specialtyUrinary systemlcsh:MedicineUrine030204 cardiovascular system & hematologyExosomesEssential hypertensionExosomeGeneral Biochemistry Genetics and Molecular BiologyExcretion03 medical and health sciences0302 clinical medicineInternal medicinemicroRNAmedicineAlbuminuriaHumansHipertensió pulmonarbusiness.industryResearchlcsh:RUrinary biomarkersGeneral MedicineMiddle Agedmedicine.diseaseMicrovesiclesmicroRNAs030104 developmental biologyEndocrinologyROC CurveHypertensionAlbuminuriaFemaleEssential Hypertensionmedicine.symptombusinessBiomarkersJournal of Translational Medicine
researchProduct